Abstract: The present application provides a splicing display unit and a display screen, in order to visually eliminate the seam, improve the user's visual effect on splicing screens, and achieve a subjective visual feeling for the user as if there was no seam. The display screen includes a plurality of display modules and a plurality of optical structures, the plurality of display modules and the plurality of optical structures being closely arranged; each of the display modules includes a display area and a black edge area arranged around the display area, black edge areas of adjacent two display modules are spliced together to form a seam; one end of the first surface of the optical structure close to the seam is a first arc surface, and the first arc surface is configured to refract light emitted from the display area of the display module, and then distribute the refracted light in a front-view area corresponding to the seam.

Abstract: Some embodiments of the present disclosure provide a laminating equipment for a Radio Frequency Identification (RFID) tire tag. The laminating equipment includes: a frame, a feeding mechanism, wherein the feeding mechanism is provided on the frame, and a laminating mechanism, wherein the laminating mechanism is provided on the frame. The laminating mechanism is configured to press rubber and an electronic chip of materials to be fed from the feeding mechanism. The feeding mechanism includes a support frame, a coiling portion which is provided on the support frame, and a driving wheel which is rotationally provided on the support frame. One end of the material to be fed is provided on the coiling portion, and the other end cooperates with the driving wheel, so as to move the material to be fed under a driving of the driving wheel. The technical solution of the present disclosure may solve a problem in the conventional art that the efficiency of manual feeding is low.

Abstract: A copolymerized crystalline latent catalyst including the reaction product of: (a) at least one crystalline acrylate monomer; (b) at least one copolymerizable catalyst compound; (c) at least one initiator; (d) at least one chain transfer agent; and (e) optionally, at least one solvent to provide a polymerized latent catalyst composition; and a process for making the above latent catalyst.

Abstract: An adhesive composition including a reaction mixture of: (A) at least one isocyanate-containing compound; (B) at least one polyol compound; and (C) a copolymerized crystalline latent catalyst; a process for making the above adhesive composition; and a laminate structure made using the above adhesive composition.

Abstract: Disclosed are 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones represented by the Formula (I): wherein Ar, R1-R6 are defined herein. Compounds having Formula (I) are PARP inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of PARP activity.

Abstract: Disclosed are 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones represented by the Formula (I): wherein Ar, R1-R6 are defined herein. Compounds having Formula (I) are PARP inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of PARP activity.

Abstract: Disclosed are 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones represented by the Formula (I): wherein Ar, R1-R6, are defined herein. Compounds having Formula (I) are PARP inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of PARP activity.

Abstract: Disclosed are 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones represented by the Formula (I): wherein Ar, R1-R6, are defined herein. Compounds having Formula (I) are PARP inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of PARP activity.

Abstract: Disclosed are 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones represented by the Formula (I): wherein Ar, R1-R6 are defined herein. Compounds having Formula (I) are PARP inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of PARP activity.

Abstract: Disclosed are 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones represented by the Formula (I): wherein Ar, R1-R6 are defined herein. Compounds having Formula (I) are PARP inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of PARP activity.

Abstract: Disclosed are 3-aryl-6-aryl-[1,2,4]triazolo[4,3-a]pyridines thereof, represented by the Formula (I) wherein Ar1, Ar2, R1-R3 are defined herein. Compounds having Formula (I) are inhibitors of cell proliferation. Therefore, compounds of the invention may be used to treat clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

Abstract: Disclosed are 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones thereof, represented by the Formula (I) wherein Ar, R1-R6 are defined herein. Compounds having Formula (I) are PARP inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of PARP activity.

Abstract: Disclosed are 3-aryl-6-aryl-[1,2,4]triazolo[4,3-?]pyridines thereof, represented by the Formula (I) wherein Ar1, Ar2, R1—R3 are defined herein. Compounds having Formula (I) are inhibitors of cell proliferation. Therefore, compounds of the invention may be used to treat clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.